PharmaTher Announces Positive Results from Study of KETABET™ for Depression
07 juin 2022 07h00 HE
|
PharmaTher Holdings Ltd.
KETABET™ (Ketamine and Betaine) shown effectiveness as measured by the Clinician Administered Dissociative States Scale Study results are adequate to give an effect size in powering a...
PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO
25 mai 2022 07h00 HE
|
PharmaTher Holdings Ltd.
Wearable ketamine delivery device complements PharmaTher’s ketamine product portfolio, including injectable, intravenous, and microneedle patch PharmaTher aims to become a leader in specialty...
PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs
05 mai 2022 07h00 HE
|
PharmaTher Holdings Ltd.
TORONTO, May 05, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce...
PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update
25 avr. 2022 17h06 HE
|
PharmaTher Holdings Ltd.
Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion product, ketamine microneedle patch and ketamine wearable...
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs
12 avr. 2022 07h00 HE
|
PharmaTher Holdings Ltd.
TORONTO, April 12, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to...
PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease
23 mars 2022 07h00 HE
|
PharmaTher Holdings Ltd.
100% of patients treated with ketamine demonstrated reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale Ketamine was well tolerated with no serious adverse events reported...
PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation
16 févr. 2022 07h00 HE
|
PharmaTher Holdings Ltd.
TORONTO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce...
PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status Epilepticus
01 févr. 2022 07h00 HE
|
PharmaTher Holdings Ltd.
TORONTO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce...
PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS
12 janv. 2022 07h00 HE
|
PharmaTher Holdings Ltd.
TORONTO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a company focused on the development and commercialization of...
PharmaTher Announces Publication of Research Data for KETABET™
04 janv. 2022 07h00 HE
|
PharmaTher Holdings Ltd.
Second published study to demonstrate the potential therapeutic utility and mechanism of action of KETABET™ (patented combination of ketamine and betaine) in models of depression Repeated use of...